J Bone Jt Infect 2019; 4(5):234-237. doi:10.7150/jbji.37980

Case Report

Dalbavancin to Treat Infected Massive Endoprostheses: A Case Report and Cost Comparison Analysis

Tariq Azamgarhi, James Donaldson, Ashik Shah, Simon Warren

Royal National Orthopaedic Hospital

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Azamgarhi T, Donaldson J, Shah A, Warren S. Dalbavancin to Treat Infected Massive Endoprostheses: A Case Report and Cost Comparison Analysis. J Bone Jt Infect 2019; 4(5):234-237. doi:10.7150/jbji.37980. Available from http://www.jbji.net/v04p0234.htm

File import instruction

Abstract

We report a case of an infected massive endoprosthetic replacement treated successfully with 2 stage surgery and off-label dalbavancin. Dalbavancin was used due to a limited number of antimicrobial options that could be administered safely in an outpatient setting and to avoid the need for daily dosing.

Keywords: Periprosthetic joint infection, Lipoglycopeptide, Coagulase negative staphylococcus epidermidis, Osteomyelitis